Compare Adaptive Biotechnologies Corp (ADPT) vs Global X Artificial Intelligence & Technology ETF (AIQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Global X Artificial Intelligence & Technology ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Global X Artificial Intelligence & Technology ETF trades at $63.92. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | AIQ | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $70.14 |
52-Week Low | $12.30 | $43.88 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
AIQ (Global X Artificial Intelligence & Technology ETF) trades at $63.77, up 0.41% with strong bullish momentum. Technical indicators show the stock above key moving averages with RSI suggesting mild overbought conditions. Recent news highlights AIQ's outperformance versus the Nasdaq, gaining 25% while attracting attention as a diversified AI play beyond semiconductor stocks. The ETF's systematic rebalancing approach positions it well for the evolving AI investment landscape.
AIQ offers exposure to the growing artificial intelligence sector with reduced single-stock risk. Key catalysts include upcoming AI company IPOs and federal quantum computing funding. Risks include thematic ETF volatility and premium fees compared to broader indices. The stock's proximity to resistance levels near $64 suggests potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →
